Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials.

ABSTRACT:

Objectives

Evaluate tofacitinib efficacy, safety and persistence by sex in rheumatoid arthritis (RA).

Design

Post hoc analyses using data from phase III placebo-controlled randomised controlled trials (ORAL Scan, ORAL Sync and ORAL Standard).

Setting

ORAL Scan, ORAL Sync and ORAL Standard were global, multicentre trials conducted across 111, 114 and 115 sites, respectively.

Participants

The trials enrolled adults with active RA and prior inadequate response to methotrexate (ORAL Scan/ORAL Standard) or ≥1 conventional synthetic or biologic disease-modifying antirheumatic drug (ORAL Sync). Post hoc analyses included 2265 patients (1870 female and 395 male).

Interventions

Patients received tofacitinib 5 mg or 10 mg two times a day, adalimumab or placebo.

SUBMITTER: Strand V 

PROVIDER: S-EPMC12746493 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature